id	sid	eid	entity	type
dpc-3517	2	1	2024;14(1):e2024026 1	DATE
dpc-3517	2	2	zhonghui qi1	PERSON
dpc-3517	2	3	xianbin liang2	PERSON
dpc-3517	2	4	jie dai1	PERSON
dpc-3517	2	5	xiaoting wei1	PERSON
dpc-3517	2	6	xue bai1	PERSON
dpc-3517	2	7	lili mao1	ORG
dpc-3517	2	8	chuanliang cui1	PERSON
dpc-3517	2	9	bin lian1	PERSON
dpc-3517	2	10	tang1	NORP
dpc-3517	2	11	xuan wang1	PERSON
dpc-3517	2	12	jun guo1	PERSON
dpc-3517	2	13	1	CARDINAL
dpc-3517	2	14	beijing	GPE
dpc-3517	2	15	peking university	ORG
dpc-3517	2	16	beijing	GPE
dpc-3517	2	17	china 2	ORG
dpc-3517	2	18	third	ORDINAL
dpc-3517	2	19	zhengzhou	GPE
dpc-3517	2	20	zhengzhou	GPE
dpc-3517	2	21	china 3	ORG
dpc-3517	2	22	fujian	GPE
dpc-3517	2	23	fujian medical university cancer hospital	ORG
dpc-3517	2	24	fuzhou	GPE
dpc-3517	2	25	fujian province	GPE
dpc-3517	2	26	china	GPE
dpc-3517	2	27	liang x	PERSON
dpc-3517	2	28	pembrolizumab	PERSON
dpc-3517	4	1	2024;14(1):e2024026	CARDINAL
dpc-3517	4	2	july 16	DATE
dpc-3517	4	3	2023	CARDINAL
dpc-3517	4	4	january 2024	DATE
dpc-3517	5	1	2024	CARDINAL
dpc-3517	6	1	https://creativecommons.org/licenses/by-nc/4.0/	ORG
dpc-3517	9	1	yu du	PERSON
dpc-3517	9	2	zhonghui qi	PERSON
dpc-3517	9	3	xianbin liang	PERSON
dpc-3517	11	1	pembrolizumab	PERSON
dpc-3517	13	1	hdi	ORG
dpc-3517	14	1	between january 2008	DATE
dpc-3517	14	2	april 2022	DATE
dpc-3517	15	1	1-year	DATE
dpc-3517	15	2	hdi	ORG
dpc-3517	16	1	seventy-five	CARDINAL
dpc-3517	16	2	6,013	CARDINAL
dpc-3517	17	1	twenty-four	CARDINAL
dpc-3517	17	2	9	CARDINAL
dpc-3517	17	3	pembrolizumab	PERSON
dpc-3517	17	4	15	CARDINAL
dpc-3517	17	5	hdi	ORG
dpc-3517	18	1	august 31	DATE
dpc-3517	18	2	2022	DATE
dpc-3517	18	3	23.6 months	DATE
dpc-3517	18	4	98.7 months	DATE
dpc-3517	18	5	hdi	ORG
dpc-3517	19	1	two	CARDINAL
dpc-3517	19	2	38.7 months	DATE
dpc-3517	19	3	0.11	CARDINAL
dpc-3517	21	1	1-year	DATE
dpc-3517	21	2	88.9%	PERCENT
dpc-3517	21	3	66.7%	PERCENT
dpc-3517	21	4	hdi	ORG
dpc-3517	22	1	1	CARDINAL
dpc-3517	22	2	2	CARDINAL
dpc-3517	22	3	3–5	CARDINAL
dpc-3517	22	4	two (13%	PERCENT
dpc-3517	22	5	hdi	ORG
dpc-3517	23	1	2	CARDINAL
dpc-3517	24	1	2024;14(1):e2024026	CARDINAL
dpc-3517	24	2	lu si	PERSON
dpc-3517	24	3	peking university	ORG
dpc-3517	24	4	52	CARDINAL
dpc-3517	24	5	haidian district	GPE
dpc-3517	24	6	beijing	GPE
dpc-3517	24	7	100142	DATE
dpc-3517	24	8	china	GPE
dpc-3517	26	1	0.7–0.8 per million	CARDINAL
dpc-3517	26	2	the first decade	DATE
dpc-3517	26	3	10 per million	CARDINAL
dpc-3517	26	4	15–19  years	DATE
dpc-3517	26	5	1	CARDINAL
dpc-3517	27	1	three	CARDINAL
dpc-3517	28	1	2	CARDINAL
dpc-3517	29	1	3	CARDINAL
dpc-3517	31	1	pembrolizumab	PERSON
dpc-3517	31	2	nivolumab	PERSON
dpc-3517	32	1	pembrolizumab	PERSON
dpc-3517	32	2	the us food and drug administration	ORG
dpc-3517	32	3	fda	ORG
dpc-3517	33	1	eight	CARDINAL
dpc-3517	34	1	pembrolizumab	PERSON
dpc-3517	34	2	4	CARDINAL
dpc-3517	36	1	ifn)-α2b	NORP
dpc-3517	36	2	hdi	ORG
dpc-3517	36	3	5	CARDINAL
dpc-3517	37	1	hdi	ORG
dpc-3517	38	1	pembrolizumab versus hdi	ORG
dpc-3517	38	2	three	CARDINAL
dpc-3517	38	3	china	GPE
dpc-3517	39	1	1	CARDINAL
dpc-3517	39	2	1	CARDINAL
dpc-3517	39	3	18-yearsold	DATE
dpc-3517	39	4	2	CARDINAL
dpc-3517	39	5	iib/iic/iii/ iv melanoma	ORG
dpc-3517	39	6	3	CARDINAL
dpc-3517	39	7	january 1, 2008 to	DATE
dpc-3517	39	8	april 30	DATE
dpc-3517	39	9	2022	CARDINAL
dpc-3517	39	10	4	CARDINAL
dpc-3517	39	11	pembrolizumab	PERSON
dpc-3517	39	12	2 mg/kg	QUANTITY
dpc-3517	39	13	200 mg	QUANTITY
dpc-3517	39	14	3 weeks	DATE
dpc-3517	39	15	hdi	ORG
dpc-3517	39	16	18×106	CARDINAL
dpc-3517	39	17	days 1–5	DATE
dpc-3517	39	18	4 weeks	DATE
dpc-3517	39	19	9×106 iu/m2	QUANTITY
dpc-3517	39	20	3 months	DATE
dpc-3517	40	1	4.03	CARDINAL
dpc-3517	41	1	first	ORDINAL
dpc-3517	42	1	1-year	DATE
dpc-3517	44	1	the institutional review board	ORG
dpc-3517	44	2	peking university	ORG
dpc-3517	44	3	helsinki	ORG
dpc-3517	46	1	kaplan-meier	ORG
dpc-3517	46	2	hdi	ORG
dpc-3517	46	3	pembrolizumab	PERSON
dpc-3517	49	1	2024;14(1):e2024026 3	DATE
dpc-3517	50	1	fisher	PERSON
dpc-3517	51	1	seventy-five	CARDINAL
dpc-3517	51	2	6013	CARDINAL
dpc-3517	51	3	three	CARDINAL
dpc-3517	51	4	between january 1, 2008	DATE
dpc-3517	51	5	april 30	DATE
dpc-3517	51	6	2022	CARDINAL
dpc-3517	52	1	twenty-eight	CARDINAL
dpc-3517	52	2	iib/iic/iii	ORG
dpc-3517	52	3	24	CARDINAL
dpc-3517	52	4	pembrolizumab	PERSON
dpc-3517	52	5	9	CARDINAL
dpc-3517	52	6	1	CARDINAL
dpc-3517	52	7	hdi	ORG
dpc-3517	52	8	15	CARDINAL
dpc-3517	52	9	2	CARDINAL
dpc-3517	53	1	12 (50%	PERCENT
dpc-3517	53	2	12 (50%	PERCENT
dpc-3517	53	3	13.5 years	DATE
dpc-3517	54	1	twenty-two	CARDINAL
dpc-3517	54	2	92%	PERCENT
dpc-3517	54	3	only two	CARDINAL
dpc-3517	54	4	8%	PERCENT
dpc-3517	55	1	18	CARDINAL
dpc-3517	55	2	three	CARDINAL
dpc-3517	55	3	one	CARDINAL
dpc-3517	55	4	two	CARDINAL
dpc-3517	56	1	one	CARDINAL
dpc-3517	56	2	two	CARDINAL
dpc-3517	56	3	nras q61r	PERSON
dpc-3517	57	1	two	CARDINAL
dpc-3517	57	2	3	CARDINAL
dpc-3517	58	1	1	CARDINAL
dpc-3517	60	1	1	CARDINAL
dpc-3517	62	1	6	CARDINAL
dpc-3517	63	1	0	CARDINAL
dpc-3517	63	2	14	CARDINAL
dpc-3517	63	3	1	CARDINAL
dpc-3517	63	4	iiic nras	PERSON
dpc-3517	63	5	15	CARDINAL
dpc-3517	63	6	0	CARDINAL
dpc-3517	63	7	15	CARDINAL
dpc-3517	63	8	1	CARDINAL
dpc-3517	63	9	11	CARDINAL
dpc-3517	63	10	0	CARDINAL
dpc-3517	63	11	7	CARDINAL
dpc-3517	63	12	0	CARDINAL
dpc-3517	63	13	14	CARDINAL
dpc-3517	63	14	iiic braf	ORG
dpc-3517	63	15	0	CARDINAL
dpc-3517	63	16	7	CARDINAL
dpc-3517	63	17	0	CARDINAL
dpc-3517	63	18	eastern cooperative oncology group	ORG
dpc-3517	64	1	4	CARDINAL
dpc-3517	65	1	2024;14(1):e2024026	CARDINAL
dpc-3517	66	1	one	CARDINAL
dpc-3517	66	2	one	CARDINAL
dpc-3517	67	1	one	CARDINAL
dpc-3517	67	2	pembrolizumab	PERSON
dpc-3517	67	3	august 31	DATE
dpc-3517	67	4	2022	CARDINAL
dpc-3517	68	1	79%	PERCENT
dpc-3517	68	2	19/24	CARDINAL
dpc-3517	68	3	44%	PERCENT
dpc-3517	68	4	4/9	CARDINAL
dpc-3517	68	5	100%	PERCENT
dpc-3517	68	6	hdi	ORG
dpc-3517	68	7	15/15	CARDINAL
dpc-3517	68	8	0.003	CARDINAL
dpc-3517	69	1	4	CARDINAL
dpc-3517	70	1	1	CARDINAL
dpc-3517	70	2	2	CARDINAL
dpc-3517	70	3	3	CARDINAL
dpc-3517	70	4	traes	ORG
dpc-3517	70	5	two	CARDINAL
dpc-3517	70	6	hdi	ORG
dpc-3517	71	1	hdi	ORG
dpc-3517	73	1	hdi	ORG
dpc-3517	73	2	2	CARDINAL
dpc-3517	73	3	1	CARDINAL
dpc-3517	73	4	2	CARDINAL
dpc-3517	73	5	1	CARDINAL
dpc-3517	73	6	1	CARDINAL
dpc-3517	73	7	1	CARDINAL
dpc-3517	73	8	1	CARDINAL
dpc-3517	73	9	1	CARDINAL
dpc-3517	73	10	leucopenia	PERSON
dpc-3517	73	11	1	CARDINAL
dpc-3517	73	12	1	CARDINAL
dpc-3517	73	13	1	CARDINAL
dpc-3517	73	14	1	CARDINAL
dpc-3517	73	15	1	CARDINAL
dpc-3517	73	16	2	CARDINAL
dpc-3517	74	1	europe	LOC
dpc-3517	74	2	6	CARDINAL
dpc-3517	75	1	august 31	DATE
dpc-3517	75	2	2022	DATE
dpc-3517	75	3	23.6 months	DATE
dpc-3517	75	4	95%	PERCENT
dpc-3517	75	5	8.9	CARDINAL
dpc-3517	75	6	98.7 months	DATE
dpc-3517	75	7	95%	PERCENT
dpc-3517	75	8	63.9	CARDINAL
dpc-3517	75	9	hdi	ORG
dpc-3517	76	1	six	CARDINAL
dpc-3517	76	2	6/9	CARDINAL
dpc-3517	76	3	67%	PERCENT
dpc-3517	76	4	10	CARDINAL
dpc-3517	76	5	67%	PERCENT
dpc-3517	76	6	hdi	ORG
dpc-3517	76	7	1 year	DATE
dpc-3517	77	1	eleven	TIME
dpc-3517	77	2	46%	PERCENT
dpc-3517	77	3	one	CARDINAL
dpc-3517	77	4	1/9	CARDINAL
dpc-3517	77	5	11%	PERCENT
dpc-3517	77	6	10	CARDINAL
dpc-3517	77	7	67%	PERCENT
dpc-3517	77	8	hdi	ORG
dpc-3517	79	1	one	CARDINAL
dpc-3517	79	2	1/9	CARDINAL
dpc-3517	79	3	11%	PERCENT
dpc-3517	79	4	five	CARDINAL
dpc-3517	79	5	5/15	CARDINAL
dpc-3517	79	6	33%	PERCENT
dpc-3517	79	7	hdi	ORG
dpc-3517	80	1	six	CARDINAL
dpc-3517	80	2	6/15, 40%	PERCENT
dpc-3517	80	3	hdi	ORG
dpc-3517	81	1	hdi	ORG
dpc-3517	81	2	38.7 months	DATE
dpc-3517	81	3	95%	PERCENT
dpc-3517	81	4	10.8	CARDINAL
dpc-3517	81	5	0.23	CARDINAL
dpc-3517	81	6	95%	PERCENT
dpc-3517	81	7	0.06–0.82	PERSON
dpc-3517	81	8	0.11	CARDINAL
dpc-3517	81	9	2	CARDINAL
dpc-3517	83	1	1-year	DATE
dpc-3517	83	2	88.9%	PERCENT
dpc-3517	83	3	95%	PERCENT
dpc-3517	83	4	70.6–100	CARDINAL
dpc-3517	83	5	66.7%	PERCENT
dpc-3517	83	6	95%	PERCENT
dpc-3517	83	7	46.6–95.3	CARDINAL
dpc-3517	83	8	2-year	DATE
dpc-3517	83	9	88.9%	PERCENT
dpc-3517	83	10	95%	PERCENT
dpc-3517	83	11	70.6–100	CARDINAL
dpc-3517	83	12	60.0%	PERCENT
dpc-3517	83	13	95%	PERCENT
dpc-3517	83	14	39.7–90.7	CARDINAL
dpc-3517	83	15	hdi	ORG
dpc-3517	84	1	five (33%	PERCENT
dpc-3517	84	2	hdi	ORG
dpc-3517	84	3	2	CARDINAL
dpc-3517	86	1	13	CARDINAL
dpc-3517	86	2	0	CARDINAL
dpc-3517	86	3	15	CARDINAL
dpc-3517	86	4	0	CARDINAL
dpc-3517	86	5	14	CARDINAL
dpc-3517	86	6	1	CARDINAL
dpc-3517	86	7	14	CARDINAL
dpc-3517	86	8	1	CARDINAL
dpc-3517	86	9	13	CARDINAL
dpc-3517	86	10	1	CARDINAL
dpc-3517	86	11	12	CARDINAL
dpc-3517	86	12	0	CARDINAL
dpc-3517	86	13	16	CARDINAL
dpc-3517	86	14	0	CARDINAL
dpc-3517	86	15	15	CARDINAL
dpc-3517	86	16	1	CARDINAL
dpc-3517	86	17	1	CARDINAL
dpc-3517	86	18	17	CARDINAL
dpc-3517	86	19	iic nras	PERSON
dpc-3517	86	20	8	CARDINAL
dpc-3517	86	21	0	CARDINAL
dpc-3517	86	22	14	CARDINAL
dpc-3517	86	23	0	CARDINAL
dpc-3517	86	24	11	CARDINAL
dpc-3517	86	25	0	CARDINAL
dpc-3517	86	26	8	CARDINAL
dpc-3517	86	27	t4an2cm0/iiic	ORG
dpc-3517	86	28	0	CARDINAL
dpc-3517	86	29	14	CARDINAL
dpc-3517	86	30	0	CARDINAL
dpc-3517	86	31	eastern cooperative oncology group	ORG
dpc-3517	88	1	2024;14(1):e2024026 5	DATE
dpc-3517	91	1	40%–50%	PERCENT
dpc-3517	92	1	8	CARDINAL
dpc-3517	93	1	iib	PRODUCT
dpc-3517	93	2	iic	PERSON
dpc-3517	94	1	3	CARDINAL
dpc-3517	96	1	1002	CARDINAL
dpc-3517	96	2	younger than	DATE
dpc-3517	96	3	10 years	DATE
dpc-3517	99	1	3	CARDINAL
dpc-3517	100	1	pembrolizumab	PERSON
dpc-3517	100	2	hdi	ORG
dpc-3517	100	3	0.290 ≤	MONEY
dpc-3517	100	4	10 3(33	CARDINAL
dpc-3517	100	5	3(20	CARDINAL
dpc-3517	100	6	0.635	CARDINAL
dpc-3517	100	7	10 6(67	CARDINAL
dpc-3517	100	8	0.089	CARDINAL
dpc-3517	100	9	2(22	CARDINAL
dpc-3517	100	10	7(78	MONEY
dpc-3517	100	11	5(33	DATE
dpc-3517	100	12	0.583	CARDINAL
dpc-3517	100	13	7(78	ORG
dpc-3517	100	14	1(11	CARDINAL
dpc-3517	100	15	2(13	CARDINAL
dpc-3517	100	16	1(11	CARDINAL
dpc-3517	100	17	0	CARDINAL
dpc-3517	100	18	0 2(13	CARDINAL
dpc-3517	100	19	0.833 ii	QUANTITY
dpc-3517	100	20	5(56	CARDINAL
dpc-3517	100	21	6(40	CARDINAL
dpc-3517	100	22	4(44	CARDINAL
dpc-3517	100	23	0 2(13	CARDINAL
dpc-3517	100	24	0.170	CARDINAL
dpc-3517	100	25	0(0	DATE
dpc-3517	101	1	1(11	CARDINAL
dpc-3517	101	2	1(7	CARDINAL
dpc-3517	101	3	nf1	ORG
dpc-3517	101	4	0(0.0	CARDINAL
dpc-3517	101	5	0(0	DATE
dpc-3517	101	6	6(67	CARDINAL
dpc-3517	101	7	1(11	CARDINAL
dpc-3517	101	8	0.669 0 7(78	PERCENT
dpc-3517	101	9	10(67	CARDINAL
dpc-3517	101	10	1 2(22	CARDINAL
dpc-3517	102	1	hdi	ORG
dpc-3517	103	1	6	CARDINAL
dpc-3517	104	1	2024;14(1):e2024026	CARDINAL
dpc-3517	104	2	11	CARDINAL
dpc-3517	105	1	one	CARDINAL
dpc-3517	105	2	fda	ORG
dpc-3517	105	3	pembrolizumab	PERSON
dpc-3517	105	4	iib	PRODUCT
dpc-3517	105	5	iic	PERSON
dpc-3517	105	6	12-month	DATE
dpc-3517	105	7	90%	PERCENT
dpc-3517	105	8	83%	PERCENT
dpc-3517	105	9	18-month	DATE
dpc-3517	105	10	86%	PERCENT
dpc-3517	105	11	77%	PERCENT
dpc-3517	105	12	2	CARDINAL
dpc-3517	106	1	kaplan-meier	ORG
dpc-3517	107	1	ci =	PERSON
dpc-3517	108	1	4	CARDINAL
dpc-3517	109	1	pembrolizumab	PERSON
dpc-3517	109	2	hdi	ORG
dpc-3517	109	3	15	CARDINAL
dpc-3517	109	4	4(44	CARDINAL
dpc-3517	109	5	0 15(100) 2(13	CARDINAL
dpc-3517	109	6	4(44	CARDINAL
dpc-3517	109	7	0 15(100) 2(13	CARDINAL
dpc-3517	109	8	1(11	CARDINAL
dpc-3517	109	9	0	CARDINAL
dpc-3517	110	1	0	CARDINAL
dpc-3517	111	1	1(11	CARDINAL
dpc-3517	111	2	0	CARDINAL
dpc-3517	112	1	1(7	CARDINAL
dpc-3517	112	2	0	CARDINAL
dpc-3517	113	1	0	CARDINAL
dpc-3517	113	2	0	CARDINAL
dpc-3517	113	3	2(22	CARDINAL
dpc-3517	113	4	0	CARDINAL
dpc-3517	113	5	1(11	CARDINAL
dpc-3517	113	6	0	CARDINAL
dpc-3517	113	7	1(7	DATE
dpc-3517	113	8	1(11	CARDINAL
dpc-3517	113	9	0	CARDINAL
dpc-3517	113	10	1(7	DATE
dpc-3517	113	11	2(22	CARDINAL
dpc-3517	113	12	0 2(13	CARDINAL
dpc-3517	113	13	0	CARDINAL
dpc-3517	114	1	0	CARDINAL
dpc-3517	115	1	0	CARDINAL
dpc-3517	115	2	0	CARDINAL
dpc-3517	115	3	1(11	CARDINAL
dpc-3517	115	4	0	CARDINAL
dpc-3517	116	1	0	CARDINAL
dpc-3517	116	2	0	CARDINAL
dpc-3517	116	3	0 0 1(7	DATE
dpc-3517	116	4	0	CARDINAL
dpc-3517	117	1	2024;14(1):e2024026 7	DATE
dpc-3517	118	1	traes	ORG
dpc-3517	119	1	two	CARDINAL
dpc-3517	119	2	5	CARDINAL
dpc-3517	119	3	4	CARDINAL
dpc-3517	120	1	traes	ORG
dpc-3517	120	2	hdi	ORG
dpc-3517	121	1	traes	ORG
dpc-3517	122	1	93%	PERCENT
dpc-3517	122	2	11%	PERCENT
dpc-3517	122	3	7%	PERCENT
dpc-3517	122	4	0	CARDINAL
dpc-3517	122	5	87%	PERCENT
dpc-3517	122	6	0	CARDINAL
dpc-3517	122	7	47%	PERCENT
dpc-3517	122	8	0	CARDINAL
dpc-3517	122	9	27%	PERCENT
dpc-3517	122	10	11%	PERCENT
dpc-3517	122	11	27%	PERCENT
dpc-3517	122	12	11%	PERCENT
dpc-3517	122	13	27%	PERCENT
dpc-3517	122	14	0	CARDINAL
dpc-3517	122	15	hdi	ORG
dpc-3517	123	1	pembrolizumab	PERSON
dpc-3517	123	2	hdi	ORG
dpc-3517	126	1	hdi	ORG
dpc-3517	128	1	hdi	ORG
dpc-3517	129	1	asian	NORP
dpc-3517	130	1	pembrolizumab	PERSON
dpc-3517	130	2	hdi	ORG
dpc-3517	130	3	two	CARDINAL
dpc-3517	131	1	pembrolizumab	PERSON
dpc-3517	132	1	pembrolizumab	PERSON
dpc-3517	132	2	hdi	ORG
dpc-3517	134	1	1	CARDINAL
dpc-3517	134	2	wong jr, harris jk	PERSON
dpc-3517	134	3	rodriguez-galindo	PERSON
dpc-3517	134	4	johnson kj	PERSON
dpc-3517	135	1	the united states	GPE
dpc-3517	135	2	1973-2009	DATE
dpc-3517	137	1	2013;131(5):846	CARDINAL
dpc-3517	137	2	2520	CARDINAL
dpc-3517	138	1	23589817	CARDINAL
dpc-3517	140	1	2	CARDINAL
dpc-3517	140	2	mohan ls	PERSON
dpc-3517	140	3	shi k	PERSON
dpc-3517	140	4	panah e	PERSON
dpc-3517	140	5	zhang b	PERSON
dpc-3517	141	1	lancet	ORG
dpc-3517	141	2	adolesc	PERSON
dpc-3517	142	1	2019;3(9):646-654	CARDINAL
dpc-3517	143	1	doi:10.1016	PERSON
dpc-3517	143	2	4642(19)30116-6	CARDINAL
dpc-3517	144	1	31204309	CARDINAL
dpc-3517	145	1	3	CARDINAL
dpc-3517	145	2	lee sj	PERSON
dpc-3517	145	3	delman ka	PERSON
dpc-3517	149	1	24022819	CARDINAL
dpc-3517	154	1	nivolumab	PERSON
dpc-3517	154	2	12	CARDINAL
dpc-3517	154	3	pembrolizumab	PERSON
dpc-3517	154	4	nct0233266849 [4	ORG
dpc-3517	154	5	13	CARDINAL
dpc-3517	155	1	14	CARDINAL
dpc-3517	155	2	only 3%	PERCENT
dpc-3517	155	3	four	CARDINAL
dpc-3517	156	1	15	CARDINAL
dpc-3517	157	1	eight	CARDINAL
dpc-3517	157	2	pembrolizumab	PERSON
dpc-3517	157	3	4	CARDINAL
dpc-3517	159	1	advl1412	GPE
dpc-3517	159	2	only two	CARDINAL
dpc-3517	159	3	55	CARDINAL
dpc-3517	160	1	16	CARDINAL
dpc-3517	163	1	7-year-old	DATE
dpc-3517	164	1	5 months	DATE
dpc-3517	164	2	1 year	DATE
dpc-3517	164	3	17	CARDINAL
dpc-3517	165	1	only one	CARDINAL
dpc-3517	165	2	1-year	DATE
dpc-3517	165	3	88.9%	PERCENT
dpc-3517	167	1	hdi	ORG
dpc-3517	167	2	pembrolizumab	PERSON
dpc-3517	171	1	keynote-051	DATE
dpc-3517	171	2	pembrolizumab	PERSON
dpc-3517	171	3	1	CARDINAL
dpc-3517	171	4	2	CARDINAL
dpc-3517	171	5	149	CARDINAL
dpc-3517	171	6	97%	PERCENT
dpc-3517	172	1	8	CARDINAL
dpc-3517	173	1	2024;14(1):e2024026	CARDINAL
dpc-3517	174	1	lancet	ORG
dpc-3517	175	1	2022;399(10336):1718-1729	CARDINAL
dpc-3517	176	1	doi:10.1016	GPE
dpc-3517	178	1	35367007	DATE
dpc-3517	179	1	12	CARDINAL
dpc-3517	180	1	davis kl	PERSON
dpc-3517	180	2	nivolumab	PERSON
dpc-3517	180	3	1-2	CARDINAL
dpc-3517	182	1	2020;21(4):541-550	CARDINAL
dpc-3517	183	1	10.1016	CARDINAL
dpc-3517	183	2	2045(20)30023-1	DATE
dpc-3517	184	1	32192573	DATE
dpc-3517	186	1	13	CARDINAL
dpc-3517	186	2	zwaan cm	PERSON
dpc-3517	186	3	marshall lv	PERSON
dpc-3517	186	4	1	CARDINAL
dpc-3517	188	1	2020;21(1):134	CARDINAL
dpc-3517	188	2	doi:10.1016	GPE
dpc-3517	188	3	2045(19)30693-x. pmid:	CARDINAL
dpc-3517	188	4	31780255	DATE
dpc-3517	189	1	14	CARDINAL
dpc-3517	190	1	loeb dm	PERSON
dpc-3517	190	2	lee jw	PERSON
dpc-3517	190	3	morgenstern da	PERSON
dpc-3517	190	4	1/2	CARDINAL
dpc-3517	191	1	immunol immun	PERSON
dpc-3517	192	1	2022;71(10):2485-2495	CARDINAL
dpc-3517	194	1	03159-8	DATE
dpc-3517	195	1	35262780	DATE
dpc-3517	196	1	pmc9463244	PERSON
dpc-3517	197	1	15	CARDINAL
dpc-3517	197	2	morgenstern da	PERSON
dpc-3517	197	3	davis kl.	PERSON
dpc-3517	198	1	american	NORP
dpc-3517	199	1	2022;(42):781-794	CARDINAL
dpc-3517	201	1	35580293	CARDINAL
dpc-3517	202	1	16	CARDINAL
dpc-3517	203	1	davis kl	PERSON
dpc-3517	203	2	reid jm	PERSON
dpc-3517	205	1	j clin oncol	PERSON
dpc-3517	206	1	2017;35(15_suppl):10526-10526	CARDINAL
dpc-3517	208	1	17	CARDINAL
dpc-3517	209	1	marjanski m	PERSON
dpc-3517	209	2	wysocki m	PERSON
dpc-3517	211	1	2019;39(7):3945-3947	CARDINAL
dpc-3517	213	1	31262925	DATE
dpc-3517	214	1	4	CARDINAL
dpc-3517	214	2	kang hj	PERSON
dpc-3517	214	3	pembrolizumab	PERSON
dpc-3517	214	4	1-2	CARDINAL
dpc-3517	216	1	2020;21(1):121	CARDINAL
dpc-3517	217	1	doi:10.1016 /s1470	PERSON
dpc-3517	219	1	31812554	DATE
dpc-3517	220	1	5	CARDINAL
dpc-3517	220	2	chao mm	PERSON
dpc-3517	220	3	schwartz	GPE
dpc-3517	220	4	wechsler ds	PERSON
dpc-3517	220	5	thornburg	PERSON
dpc-3517	220	6	griffith ka	PERSON
dpc-3517	220	7	williams ja.	PERSON
dpc-3517	222	1	2005;44(5):441-448	CARDINAL
dpc-3517	223	1	15468307	DATE
dpc-3517	224	1	6	CARDINAL
dpc-3517	224	2	ferrari	ORG
dpc-3517	225	1	bisogno g	PERSON
dpc-3517	225	2	perilongo g	PERSON
dpc-3517	225	3	italian	NORP
dpc-3517	225	4	trep	ORG
dpc-3517	227	1	2007;43(4):654-659	CARDINAL
dpc-3517	228	1	17049226	CARDINAL
dpc-3517	229	1	7	CARDINAL
dpc-3517	229	2	pampena	PERSON
dpc-3517	229	3	muscianese	NORP
dpc-3517	231	1	2023;37(9):1758-1776	CARDINAL
dpc-3517	232	1	doi:10.1111	ORG
dpc-3517	233	1	37210654	DATE
dpc-3517	234	1	8	CARDINAL
dpc-3517	235	1	weber j	PERSON
dpc-3517	235	2	mandala m	PERSON
dpc-3517	235	3	del vecchio m	ORG
dpc-3517	238	1	2017;377(19):1824-1835	DATE
dpc-3517	240	1	pmid	PERSON
dpc-3517	240	2	28891423	CARDINAL
dpc-3517	241	1	9	CARDINAL
dpc-3517	241	2	cu	ORG
dpc-3517	241	3	mandala m	ORG
dpc-3517	243	1	2018;378(19):1789-1801	DATE
dpc-3517	244	1	1802357	DATE
dpc-3517	245	1	29658430	DATE
dpc-3517	246	1	10	CARDINAL
dpc-3517	246	2	cu	ORG
dpc-3517	246	3	mandala m	ORG
dpc-3517	247	1	eortc1325	PERSON
dpc-3517	249	1	2019;116:148-157	CARDINAL
dpc-3517	249	2	doi:10.1016/j.ejca.2019.05.020	ORG
dpc-3517	250	1	31200321	DATE
dpc-3517	251	1	11	CARDINAL
dpc-3517	252	1	luke jj,	PERSON
dpc-3517	252	2	rutkowski p	PERSON
dpc-3517	252	3	queirolo p	PERSON
dpc-3517	252	4	pembrolizumab	PERSON
dpc-3517	252	5	iib	PRODUCT
dpc-3517	252	6	iic	PERSON
dpc-3517	252	7	3	CARDINAL